CARDINAL HEALTH INC Form 8-K July 10, 2009

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 9, 2009

# Cardinal Health, Inc.

(Exact name of registrant as specified in its charter)

Ohio (State or other jurisdiction

1-11373 (Commission File Number) 31-0958666 (IRS Employer

of incorporation)


**Identification No.)** 

**7000 Cardinal Place, Dublin, Ohio** (Address of principal executive offices)

43017 (Zip Code)

(614) 757-5000

(Registrant s telephone number, including area code)



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01 Regulation FD Disclosure

On July 10, 2009, CareFusion Corporation ( CareFusion ), the entity that is currently a wholly owned subsidiary of Cardinal Health, Inc. (the Company ) and that is expected to become public as a result of the planned spin-off of the Company s clinical and medical products businesses, issued a press release announcing that it will resume shipping Alaris® PC units and Alaris® PCA (Patient Controlled Analgesia) modules. A copy of the news release is included as Exhibit 99.1 to this report.

#### Item 8.01 Other Events

As previously reported, on April 24, 2009, the Company submitted the corrective action plan required by the Amended Consent Decree for Condemnation and Permanent Injunction between a subsidiary of the Company and the U.S. Food and Drug Administration (the FDA). Included in the corrective action plan was, among other proposed corrective actions, a software correction that addresses the potential risk recently identified with the Alaris PCA module when used with the Alaris PC Unit operating with software versions 8 through 9.1. When the products are used together, the Alaris PCA module may infuse above or below the intended infusion dose if a specific sequence of events occurs. The Company had placed a hold on shipping the Alaris PCA module and related Alaris PC Unit until the software was corrected. On July 9, 2009, the Company received FDA 510(k) clearance for the software correction, which allows the Company to resume shipping the Alaris PC unit and Alaris PCA module. See the Company s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed on May 7, 2009 and Amendment No. 5 to CareFusion s Form 10 registration statement filed on July 8, 2009 for additional information on this matter.

#### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 News release issued by CareFusion Corporation on July 10, 2009.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cardinal Health, Inc. (Registrant)

Date: July 10, 2009

By: /s/ Craig S. Morford
Name: Craig S. Morford

Title: Chief Legal and Compliance Officer

#### EXHIBIT INDEX

99.1 News release issued by CareFusion Corporation on July 10, 2009.

- 4 -